JACKLYN EYRE: Open Payments
NPI 1336487198 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,818 in 80 payments from 15 companies in 2025. Trend: 2023 $2,258 · 2024 $1,852 · 2025 $1,818
Food & beverage: $1,818
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 35 | $583 |
| Amgen Inc. | 14 | $290 |
| Lilly USA, LLC | 10 | $276 |
| AstraZeneca Pharmaceuticals LP | 4 | $261 |
| Corcept Therapeutics | 2 | $105 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $63 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $46 |
| GlaxoSmithKline, LLC. | 2 | $43 |
| ABBVIE INC. | 2 | $30 |
| Biogen, Inc. | 1 | $25 |
Products named: Ozempic, FARXIGA, EVENITY, ZEPBOUND, MOUNJARO, Wegovy, Korlym, JARDIANCE.
Industry payments across TX — which companies pay providers there.
